Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of the present study was to evaluate the additional effect of sudden visceral fat reduction by omentectomy on Metabolic Syndrome, acute phase reactants and inflammatory mediators in patients with morbid obesity undergoing Laparoscopic Roux-en-Y Gastric Bypass.
Although weight loss controls Metabolic Syndrome and reduces the level of inflammatory markers in patients with Morbid Obesity, patients may enjoy the benefit achieving metabolic control before significant weight loss occurs.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Roux-en-Y Gastric Bypass/Omentectomy | Experimental | Laparoscopic Roux-en-Y Gastric Bypass with omentectomy |
|
| Roux-en-Y Gastric Bypass alone | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Laparoscopic Roux-en-Y Gastric Bypass | Procedure | Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy. |
| Measure | Description | Time Frame |
|---|---|---|
| Components of Metabolic Syndrome (Body Mass Index) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Components of Metabolic Syndrome (Body Mass Index) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 month |
| Components of Metabolic Syndrome (Body Mass Index) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Components of Metabolic Syndrome (Body Mass Index) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Components of Metabolic Syndrome (Body Mass Index) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
| Components of Metabolic Syndrome (Systolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Components of Metabolic Syndrome (Systolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. |
| Measure | Description | Time Frame |
|---|---|---|
| Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement | Basal |
| Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Miguel F Herrrera, MD, PhD | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Principal Investigator |
Not provided
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 20587720 | Derived | Herrera MF, Pantoja JP, Velazquez-Fernandez D, Cabiedes J, Aguilar-Salinas C, Garcia-Garcia E, Rivas A, Villeda C, Hernandez-Ramirez DF, Davila A, Zarain A. Potential additional effect of omentectomy on metabolic syndrome, acute-phase reactants, and inflammatory mediators in grade III obese patients undergoing laparoscopic Roux-en-Y gastric bypass: a randomized trial. Diabetes Care. 2010 Jul;33(7):1413-8. doi: 10.2337/dc09-1833. |
Not provided
Not provided
Not provided
Patients from the obesity clinic were recruited from November 2005 to October 2006
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Roux-en-Y Gastric Bypass/Omentectomy | |
| FG001 | Roux-en-Y Gastric Bypass Alone |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Roux-en-Y Gastric Bypass/Omentectomy | |
| BG001 | Roux-en-Y Gastric Bypass Alone | |
| BG002 | Total |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Components of Metabolic Syndrome (Body Mass Index) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | Kg/m2 | Basal |
|
|
Not provided
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Roux-en-Y Gastric Bypass/Omentectomy |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Pancreatic Fistula | Surgical and medical procedures | MeSH 2008 | Systematic Assessment |
Not provided
An important limitation of our study is the small number of studied patients.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Miguel F Herrera | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | (+52) 55 54870208 | miguelfherrera@gmail.com |
Not provided
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| D009767 | Obesity, Morbid |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Omentectomy | Procedure | After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag. |
|
| 1 month |
| Components of Metabolic Syndrome (Systolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Components of Metabolic Syndrome (Systolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Components of Metabolic Syndrome (Systolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
| Components of Metabolic Syndrome (Diastolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Components of Metabolic Syndrome (Diastolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 month |
| Components of Metabolic Syndrome (Diastolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Components of Metabolic Syndrome (Diastolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Components of Metabolic Syndrome (Diastolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
| Components of Metabolic Syndrome (Glucose) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Components of Metabolic Syndrome (Glucose) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 month |
| Components of Metabolic Syndrome (Glucose) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Components of Metabolic Syndrome (Glucose) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Components of Metabolic Syndrome (Glucose) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
| Components of Metabolic Syndrome (Insulin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Components of Metabolic Syndrome (Insulin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Components of Metabolic Syndrome (Insulin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Components of Metabolic Syndrome (Insulin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
| Components of Metabolic Syndrome (Total Cholesterol) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Components of Metabolic Syndrome (Total Cholesterol) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 month |
| Components of Metabolic Syndrome (Total Cholesterol) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Components of Metabolic Syndrome (Total Cholesterol) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Components of Metabolic Syndrome (Total Cholesterol) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
| Components of Metabolic Syndrome (Triglycerides) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Components of Metabolic Syndrome (Triglycerides) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 month |
| Components of Metabolic Syndrome (Triglycerides) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Components of Metabolic Syndrome (Triglycerides) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Components of Metabolic Syndrome (Triglycerides) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
| Components of Metabolic Syndrome (Low-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Components of Metabolic Syndrome (Low-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 month |
| Components of Metabolic Syndrome (Low-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Components of Metabolic Syndrome (Low-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Components of Metabolic Syndrome (Low-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
| Components of Metabolic Syndrome (High-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Components of Metabolic Syndrome (High-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 month |
| Components of Metabolic Syndrome (High-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Components of Metabolic Syndrome (High-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Components of Metabolic Syndrome (High-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. |
| 3 months |
| Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
| Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement | Basal |
| Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement | 1 year |
| Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement | 6 months |
| Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
| Acute Phase Reactants and Inflammatory Mediators (Leptin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Acute Phase Reactants and Inflammatory Mediators (Leptin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Acute Phase Reactants and Inflammatory Mediators (Leptin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Acute Phase Reactants and Inflammatory Mediators (Leptin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
| Acute Phase Reactants and Inflammatory Mediators (Adiponectin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Basal |
| Acute Phase Reactants and Inflammatory Mediators (Adiponectin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 3 months |
| Acute Phase Reactants and Inflammatory Mediators (Adiponectin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 6 months |
| Acute Phase Reactants and Inflammatory Mediators (Adiponectin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | 1 year |
Total of all reporting groups
| Participants |
|
| Age Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement | Posted | Mean | Standard Deviation | pg/ml | Basal |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Body Mass Index) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Median | Standard Deviation | Kg/m2 | 1 month |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Body Mass Index) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | Kg/m2 | 3 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Body Mass Index) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | Kg/m2 | 6 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Body Mass Index) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | Kg/m2 | 1 year |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Systolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mmHg | Basal |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Systolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mmHg | 1 month |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Systolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mmHg | 3 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Systolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mmHg | 6 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Systolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mmHg | 1 year |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Diastolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mmHg | Basal |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Diastolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mmHg | 1 month |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Diastolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mmHg | 3 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Diastolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mmHg | 6 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Diastolic Blood Pressure) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mmHg | 1 year |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Glucose) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | Basal |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Glucose) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 1 month |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Glucose) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 3 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Glucose) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 6 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Glucose) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 1 year |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Insulin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | μU/μL | Basal |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Insulin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | μU/μL | 3 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Insulin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | μU/μL | 6 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Insulin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | μU/μL | 1 year |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Total Cholesterol) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | Basal |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Total Cholesterol) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 1 month |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Total Cholesterol) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 3 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Total Cholesterol) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 6 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Total Cholesterol) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 1 year |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Triglycerides) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | Basal |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Triglycerides) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 1 month |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Triglycerides) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 3 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Triglycerides) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 6 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Triglycerides) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 1 year |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Low-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | Basal |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Low-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 1 month |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Low-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 3 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Low-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 6 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (Low-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 1 year |
|
|
|
|
| Primary | Components of Metabolic Syndrome (High-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | Basal |
|
|
|
|
| Primary | Components of Metabolic Syndrome (High-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 1 month |
|
|
|
|
| Primary | Components of Metabolic Syndrome (High-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 3 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (High-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 6 months |
|
|
|
|
| Primary | Components of Metabolic Syndrome (High-Density Lipoproteins) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | mg/dl | 1 year |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | pg/ml | 3 months |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | pg/ml | 6 months |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Interleukine-6) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | pg/ml | 1 year |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement | Posted | Mean | Standard Deviation | μg/mL | Basal |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | μg/mL | 3 months |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | μg/mL | 6 months |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (C-reactive Protein) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement | Posted | Mean | Standard Deviation | μg/mL | 1 year |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | pg/ml | Basal |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | pg/ml | 3 months |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement | Posted | Mean | Standard Deviation | pg/ml | 6 months |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Tumor Necrosis Factor-alpha) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | pg/ml | 1 year |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Leptin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | ng/ml | Basal |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Leptin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Error | ng/ml | 3 months |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Leptin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | ng/ml | 6 months |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Leptin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | ng/ml | 1 year |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Adiponectin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | ng/ml | Basal |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Adiponectin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | ng/ml | 3 months |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Adiponectin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | ng/ml | 6 months |
|
|
|
|
| Secondary | Acute Phase Reactants and Inflammatory Mediators (Adiponectin) | Absolute values are presented, a basal value is provided in a previous outcome measure to determine the improvement. | Posted | Mean | Standard Deviation | ng/ml | 1 year |
|
|
|
|
| 1 |
| 12 |
| 0 |
| 12 |
| EG001 | Roux-en-Y Gastric Bypass Alone | 0 | 12 | 0 | 12 |
Not provided
Not provided
Not provided
| D009750 |
| Nutritional and Metabolic Diseases |
| D009765 | Obesity |
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D001835 | Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |